Although tirzepatide was created to combat type 2 diabetes, it has also been demonstrated to safeguard the cardiovascular system. The synthetic gastric inhibitory polypeptide (GIP) derivative tirzepatide also functions as glucagon-like peptide-1 (GLP-1). Because of this combination, tirzepatide can improve insulin sensitivity, decrease blood glucose levels, and promote sensations of fullness.